EP3191092A4 - Targeting k-ras-mediated signaling pathways and malignancy by prostratin - Google Patents

Targeting k-ras-mediated signaling pathways and malignancy by prostratin Download PDF

Info

Publication number
EP3191092A4
EP3191092A4 EP15839485.8A EP15839485A EP3191092A4 EP 3191092 A4 EP3191092 A4 EP 3191092A4 EP 15839485 A EP15839485 A EP 15839485A EP 3191092 A4 EP3191092 A4 EP 3191092A4
Authority
EP
European Patent Office
Prior art keywords
prostratin
malignancy
ras
targeting
signaling pathways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15839485.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3191092A1 (en
Inventor
Frank Mccormick
Man-Tzu WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP3191092A1 publication Critical patent/EP3191092A1/en
Publication of EP3191092A4 publication Critical patent/EP3191092A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP15839485.8A 2014-09-10 2015-09-10 Targeting k-ras-mediated signaling pathways and malignancy by prostratin Withdrawn EP3191092A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048761P 2014-09-10 2014-09-10
PCT/US2015/049459 WO2016040656A1 (en) 2014-09-10 2015-09-10 Targeting k-ras-mediated signaling pathways and malignancy by prostratin

Publications (2)

Publication Number Publication Date
EP3191092A1 EP3191092A1 (en) 2017-07-19
EP3191092A4 true EP3191092A4 (en) 2018-04-25

Family

ID=55459578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15839485.8A Withdrawn EP3191092A4 (en) 2014-09-10 2015-09-10 Targeting k-ras-mediated signaling pathways and malignancy by prostratin

Country Status (7)

Country Link
US (1) US10201516B2 (zh)
EP (1) EP3191092A4 (zh)
JP (1) JP2017527583A (zh)
CN (1) CN106659705A (zh)
AU (1) AU2015314979A1 (zh)
CA (1) CA2958683A1 (zh)
WO (1) WO2016040656A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005994A1 (en) * 2016-07-01 2018-01-04 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
US11147809B2 (en) 2010-08-27 2021-10-19 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
CA2958683A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by prostratin
CN108467874A (zh) * 2018-04-04 2018-08-31 首都医科大学附属北京朝阳医院 利用Crispr技术敲除Cosmc基因构建的O-型糖基化异常的结肠癌细胞系
CN114786697A (zh) * 2019-09-24 2022-07-22 K-Gen股份有限公司 作用于蛋白激酶c(pkc)的二萜类化合物
WO2022048574A1 (zh) * 2020-09-01 2022-03-10 上药生物治疗（香港）有限公司 一种编码Kras基因突变体的核酸分子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110006A2 (en) * 2012-01-18 2013-07-25 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2557070B2 (ja) 1987-09-28 1996-11-27 財団法人微生物化学研究会 新規生理活性物質プロベスチン、プロスタチン及びその製造法
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US8067632B2 (en) 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
EP2276478A4 (en) 2008-04-11 2012-03-07 Aids Res Alliance METHOD FOR THE ADMINISTRATION OF PROSTRATIN AND STRUCTURAL ANALOGUE THEREOF
US8816122B2 (en) 2009-07-20 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
CA2958683A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by prostratin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110006A2 (en) * 2012-01-18 2013-07-25 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. FERNANDEZ-MEDARDE ET AL: "Ras in Cancer and Developmental Diseases", GENES AND CANCER, vol. 2, no. 3, 1 March 2011 (2011-03-01), US, pages 344 - 358, XP055459147, ISSN: 1947-6019, DOI: 10.1177/1947601911411084 *
JANE A. BOND ET AL: "Cytotoxic action of phorbol esters on human pancreatic cancer cells", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 7, 1 January 2007 (2007-01-01), US, pages 1445 - 1454, XP055459531, ISSN: 0020-7136, DOI: 10.1002/ijc.22869 *
See also references of WO2016040656A1 *
WANG MAN-TZU ET AL: "K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling", CELL, CELL PRESS, vol. 163, no. 5, 19 November 2015 (2015-11-19), pages 1237 - 1251, XP029306460, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2015.10.041 *

Also Published As

Publication number Publication date
EP3191092A1 (en) 2017-07-19
US10201516B2 (en) 2019-02-12
CN106659705A (zh) 2017-05-10
AU2015314979A1 (en) 2017-03-02
US20170326093A1 (en) 2017-11-16
CA2958683A1 (en) 2016-03-17
WO2016040656A1 (en) 2016-03-17
JP2017527583A (ja) 2017-09-21

Similar Documents

Publication Publication Date Title
EP3223735A4 (en) Visualization catheters
EP3177551A4 (en) Order fulfillment technique
EP3115076A4 (en) Catheter
GB201418455D0 (en) Q-flow HLS
EP3119885A4 (en) Antibody-fynomer conjugates
EP3164074A4 (en) Alignment ct
IL250393A0 (en) Tubular assembly
EP3129064A4 (en) Targeted therapeutics
EP3131586A4 (en) Targeted therapeutics
EP3471539A4 (en) SIGNALING PROCESSING WITH KLRG1
EP3151907A4 (en) Tubing assembly
EP3099332A4 (en) Targeted therapeutics
IL251976A0 (en) Phage therapy
EP3120890A4 (en) Catheter
EP3094200A4 (en) Mandible shield
EP3191129A4 (en) TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3189872A4 (en) Catheter
EP3191092A4 (en) Targeting k-ras-mediated signaling pathways and malignancy by prostratin
EP3174591A4 (en) Transcarotid neurovascular catheter
EP3187215A4 (en) Needless injector
EP3178386A4 (en) Catheter
EP3367914A4 (en) ECHOGEN NEEDLE
EP3171876A4 (en) Combination therapy
EP3159009A4 (en) Apoptosis inducer
EP3172535A4 (en) Sonde

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180323

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20180319BHEP

Ipc: A61K 31/22 20060101AFI20180319BHEP

Ipc: A61P 35/00 20060101ALI20180319BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181023